StockData
Silence Therapeutics plc logo

Silence Therapeutics plc (SLN) income statement

SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$19.82+0.02 (+0.10%)

Close on Nov 18, 2026Market cap $936.43MP/E –Yield –

Silence Therapeutics plc income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
95.0%
Operating margin
-12343.6%
Net margin
-11276.5%
Return on equity, FY2025
-90.3%

Financial strength

Current ratio
23.94
Debt to equity
–
Debt to assets
–
Cash to current liabilities
2199.7%

Valuation

P/E ratio
–
Price to sales
2053.57
Price to book
4.36
Dividend yield
–

See a number that looks wrong?